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ABSTRACT 
Background : The 3-hydroxy-3-methylglutaryl-coenzyme (HMG-Co-A) reductase inhibitors, also known as statins, 
are the most effective class of drugs for lowering serum Low-Density Lipoprotein cholesterol (LDL-c) 
concentrations. They are first-line agents for patients who require drug therapy to reduce serum LDL-c 
concentrations. Although these drugs have been very successful in managing the cardiovascular health of many 
patients, there are also potential adverse effects that have been identified. The most common adverse effects 
reported include muscle pain or weakness that can progress to rhabdomyolysis and mortality. If detected early, 
statin-related symptoms are reversible after withdrawal of the statin.  
Objective : This research was aimed to know  the safety of  statin used  at Public Hospitals in Yogyakarta.  
Method : This research was observational study with retrospective data collected. The target population are all of 
diabetes mellitus, cardiovascular and stroke patients that recorded on the medical record of Public Hospitals in 
Yogyakarta during 2 months.  
Results : There were 28 patients who  used simvastatin and 8 patients  who used atorvastatin, experienced adverse 
effects of statins (n=157). Headache was the most adverse effect which was experienced by the patients. However 
rhabdomyolysis was not found in this reasearh. Interaction between simvastatin and nifedipine resulted more 
adverse effects such as headache, insomnia and abdominal pain than with other drugs. 
Conclusions : Simvastatin, rosuvastatin and atorvastatin were well tolerated use in Yogyakarta, Indonesia. Only 22.9% 
from 157 patients experienced the adverse effects of statin.  Adverse effects because of the interaction between 
simvastatin and other drugs were experienced by 8.92% patients.  The result of this study need to be confirmed with 
additional study with larger sample sizes and vigilant surveillance to abolish the toxicity of the statin. 
Keywords: Statin, Adverse Effects, Indonesia 
INTRODUCTION 
Many people have high blood cholesterol that 
may lead to Coronary Heart Disease (CHD). 
A multifaceted approach consisting of diet, 
exercise, and pharmacological management is 
recommended to lower the risk of CHD. 
Elevated low-density lipoprotein-cholesterol 
(LDL-C) has been established as a major 
cause of CHD1. 
In Indonesia, although not yet having the 
national data of the prevalence of CHD, the 
serious impact of this illness was seen. The 
CHD occupied the first place of all the death 
that was 16% in the survey of the health of 
the household (SKRT) 1992 and increased to 
18.9% in SKRT 1995.  Otherwise the  
Surkesnas 2001 showed the figure of CHD 
was 26,4% 2. The increase of low-density-
lipoprotein-chlesterol (LDL-C) was the main 
cause of the coronary heart disease 1. 
Moreover, the diabetes  melitus was one of 
the main factors the cause of the risk 
emergence of the CHD that as a result of by 
hyperlipidemia 3. Indonesia occupied the 4th 
place biggest in the world in the number of 
diabetes melitus (8.6% from the total 
population) 4. 
The group of cholesterol-lowering drugs 
known as statins are widely and successfully 
used in the management of atherosclerotic 
disease processes that include CHD, 
myocardial infarction, stroke, and peripheral 
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vascular disease. Statins inhibit the formation 
of HMG-Co-A reductase, which is essential 
in forming mevalonate, a precursor to 
cholesterol and other compounds. Lowering 
LDL-C is the goal of statin therapy, and 
multiple studies indicated that lowering LDL-
C decreases the risk for CHD in people 
without a history of CHD and decreases the 
risk for cardiovascular events in people with a 
history of CHD. Six statins are currently 
available, such as: atorvastatin, fluvastatin, 
lovastatin, pravastatin, rosuvastatin, and 
simvastatin1. 
Although these drugs have been very 
successful in managing the cardiovascular 
health of many patients, there are also 
potential adverse effects that have been 
identified. Statins are generally used for long-
term exposure. Longer durations of therapy 
would be anticipated in younger patients with 
less overt vascular disease. Acquisition of 
safety data are also cumulative, because the 
safety profile of a pharmaceutical agent 
becomes more precise with increasing 
exposure of the molecule to subjects. During 
initial drug development, animal toxicology is 
used to recognize those compounds that have 
already raised possible safety concerns before 
clinical evaluation. Early short-term clinical 
efficacy studies, as designed, can only be 
expected to detect adverse events that occur 
with relatively high frequency. Indeed, it is 
acknowledged that regulatory approval for 
clinical use “does not and cannot guarantee 
safety” 1. 
The most common adverse effects reported 
include muscle pain or weakness that can 
progress to rhabdomyolysis and mortality. If 
detected early, statin-related symptoms are 
reversible after withdrawal of the statin. Early 
identification of these potentially serious 
adverse effects makes the information in this 
update critical for physical therapists, because 
they frequently screen patients with 
musculoskeletal complaints 1. 
Considering that more than 76 million 
prescriptions for statins in 2000, there was 
increased concern about the safety of statins. 
One statin, cerivastatin, was voluntarily 
withdrawn from the market by the 
manufacturer in 2001, following its 
implication in severe adverse muscle 
reactions and death. In 2002, the American 
College of Cardiology, the American Heart 
Association, and the National Heart, Lung 
and Blood Institute (ACC/AHA/ NHLBI) 
issued a clinical advisory about the use of 
statins1,5 . 
One of the risk factor that might increase the 
adverse effects of statin used is drug 
interaction. The cytochrome P450 (CYP) 
isoform CYP3A4 serves as the major 
pathway for metabolism of lovastatin, 
simvastatin, atorvastatin, and cerivastatin . 
Inhibition of the activity of CYP3A4 can 
increase serum levels of these statins, which 
raises the potential for adverse effects. 
Pravastatin does not undergo metabolism 
through the CYP450 system but is 
metabolized by sulfation and conjugation. 
Fluvastatin is metabolized mainly by 
CYP2C9 and to a lesser extent by CYP3A4 
and CYP2D6. Rosuvastatin is metabolized 
mainly by CYP2C9 and CYP2C19. Although 
it was initially suspected that gemfibrozil 
increased statin levels by inhibiting CYP450 
enzymes, it is now thought that its inhibition 
of glucuronidation of statins may be a likely 
culprit. Gemfibrozil undergoes extensive 
glucuronidation by the UDP-
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glucuronosyltransferase (UGT) isoforms 
UGT1A1 and UGT1A3, which also mediate 
glucuronidation of statins. Glucuronidation is 
now recognized as a major pathway for 
elimination of the active hydroxy acid 
metabolites of statins. Fenofibrate does not 
appear to interfere with the UGT1A1 and 
UGT1A3 enzymes that mediate statin 
glucuronidation (fenofibrate is glucuronidated 
by UGT1A9 and UGT2B7).  Perhaps statin 
fenofibrate combinations may have less risk 
for interactions than therapy with statins and 
gemfibrozil 6. 
The purpose of this article is to describe the 
adverse effects of statins so that physical 
therapists will be better prepared to recognize 
possible statin-adverse effects  
MEHODS 
Patients  
We investigated the medical record of all 
patients with diabetes melitus, CHD and 
stroke that was given the statins’ group in 
Yogyakarta hospitals during 2 months.  
Eligible patients were men and women 
between 18 and 80 years of age. 
Study design 
The research was observational study and the 
data was collected retrospectively. We 
investigate  the patients’complaints in the 
medical record during the use of statins’group 
for 2 months. 
Data analysis 
Data was analysed descriptively by counting 
the percentage of patients who experienced 
the adverse effects of statins. 
RESULT AND DISCUSSION 
The safety of a pharmaceutical agent is a 
relative term. Safety concerns for agents used 
long-term in the treatment of relatively well 
individuals as preventive therapies would 
differ from those for agents used for the 
treatment of life-threatening illnesses for 
shorter durations.  
One hundred and fifty seven patients were 
included in this study. Demographics data of 
the patients were listed in Table 1. 
Table 1: Patients’ demographics data 
Patients’ data   
Age Mean ± SD  
Male 56.43 ± 12.44  
Female 57.73 ± 10.73  
 Total number Percentage (%) 
Sex   
Male 93 59.24 
Female 64 60.76 
Diagnosa   
Diabetes mellitus 42 26.75 
CHD 76 48.41 
Stroke 27 17.20 
Others 12 7.64 
Statin used   
Simvastatin 120 76.43 
Atorvastatin 34 21.66 
Rosuvastatin 3 1.91 
 
 
233
We recruited 157 patients with diabetes 
mellitus, cardiovascular, stroke and other 
patients (93 males and 64 females). The 
most number of patients were used 
simvastatin (76.43%), however rosuvastatin 
were rare to used in Indonesia (1.91%), this 
was caused by uncovered price of 
rosuvastatin in Indonesia. 
The adverse effects that were caused by the 
use statins’ group in hospitalized patient 
with diabetes melitus, CHD and stroke 
could be seen in the figure 1. 
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Fig. 1. Adverse effects of simvastatin and atorvastatin 
In this study, the number of patients who 
experienced the adverse effect because of the 
use simvastatin were 28 patients and 8 
patients used atorvastatin. The patients who 
experienced the headache were 9 patients 
(5.73%). The headache adverse effects was 
happened after the use simvastatin for 1-2 
days. Based on the characteristics of its 
chemical physics, simvastatin had the 
penetration capacity to the central nervous 
system so as to be able to disrupt the central 
nervous system and may cause the headache. 
Moreover, other factors that caused this 
adverse effect from the use simvastatin is the 
existence of the patients who suffered 
hypertension that was shown with the 
increase in blood pressure and other illness 
like diabetes mellitus and hyperglicemia. 
Several illnesses could cause the headache. 
So this adverse effect could be caused by two 
matters, in case, the use of simvastatin and 
the existence of the risk factor of the illness 
that was suffered by the patient.  
Insomnia was experienced by 4 patients 
(2.54%). Based on the characteristics of its 
chemical physics, simvastatin was 
hydrophobic, so it could penetrate blood brain 
barrier and reached the central nervous 
system. Simvastatin could influence the 
activity of the brain, including the activity of 
the brain that was connected with the sleep 
regulation so as to be able to cause the 
adverse effect to be difficult to sleep. 
Moreover, this adverse effect then possibly 
was caused because of the condition for the 
patient who suffered the diabetes  mellitus, 
hyperglicemia, and CHD that was marked by 
the breathless existence, chest pain, and other 
factors that caused the function situation of 
his body to descend and trigger the 
disturbance emergence of thoughts to the 
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patient so as to cause the adverse effect to be 
difficult to sleep. 
The other adverse effect that happened 
because of simvastatin was abdominal pain. 
This adverse effect was experienced by 
patients with the percentage 5.54%. The 
adverse effect was happened after the use 
simvastatin for several days. 
All of the statins are rarely associated with 
elevations in liver transaminase levels (>3X 
ULN), occurring in approximately 3.09% of 
patients. The clinical significance of 
asymptomatic liver enzyme elevations from 
statins has been questioned, however. The 
risk increases with increasing doses. In the 
previous study comparing atorvastatin 80mg 
to simvastatin 80mg daily, there was a 
significantly higher incidence of transaminase 
elevation in the atorvastatin group compared 
to simvastatin. The reduction in LDL-c was 
greater with atorvastatin 80 mg compared 
with simvastatin 80 mg (53.6% vs 48.1%; 
p<0.001) in the same study7. 
Rhabdomyolisis was not found in this study. 
The symptoms progress toward 
rhabdomyolysis as long as patients continue 
to take the drug. Rhabdomyolysis is a 
syndrome that results from severe skeletal 
muscle injury and lysis, causing the 
widespread release of myoglobin with dark 
brown urine secondary to myoglobinuria. An 
analysis of data from the Adverse Event 
Reporting System (AERS) of the FDA 
showed that as of June 2001, fatal 
rhabdomyolysis had been reported at rates of <1 
death per 1 million prescriptions for all statins, 
except cerivastatin, which had an incidence of 
>3 deaths per 1 million prescriptions8. 
However, there were 4 patients experienced 
the increase of ureum and creatinin. The 
occurrence of renal toxicity relatively early 
after initiation of therapy (within the first 12 
weeks on average), suggests that vigilant 
surveillance for adverse effects during 
initiation of therapy may help ameliorate the 
risk of toxicity, especially in rosuvastatin 9. 
The interaction of simvastatin and other drugs 
could be seen on figure 2.  In this research, 
there were some medicine that were 
interacted with simvastatin through the 
mechanism of the enzyme inhibition 
CYP3A4. The parameter that was seen was 
the patient's complaint was recorded in 
medical record after the patient used 
simvastatin with other medicine and caused 
the adverse effect. 
0
0,5
1
1,5
2
2,5
3
%
Headache Insomnia Abdominal pain Anorexia
Adverse effects
Nifedipine Diltiazem Amiodaron Methyl prednisolone
 
Fig. 2 : Adverse effects which were caused by interaction between simvastatin and other drugs. 
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Some drugs interacted with simvastatin both 
through the mechanism of the induction and 
the enzyme inhibition CYP3A4. These drugs 
were nifedipine, amiodarone, diltiazem, and 
methyl prednisolon. The four drugs inhibited 
CYP3A4 sub-enzyme. With this mechanism, 
the level of simvastatin in plasma will 
increase so as to have the potential to cause 
the adverse effect 8.  
Nifedipine was a calcium channel blocker 
that often was used in hypertension medical 
treatment. Nifedipine experienced extensive 
metabolism pre-systemic with orally 
bioavailability of 45%. Nifedipine also 
showed high plasma clearens that was caused 
by the hepatic extraction. The metabolism of 
nifedipine took the form of first stage 
oxidation formed pyridin analogous 
metabolite that joined with the acid 
metabolite formation which was excreted in 
the urine. Nifedipine interacted with 
simvastatin through the CYP P450 pathway 8. 
The competition happen between simvastatin 
and nifedipine to bind in the active site of 
CYP3A4. The occurrence of the competition 
between simvastatin and nifedipine could 
cause the number simvastatin fewer than that 
without the existence of nifedipine. 
Moreover, the use simvastatin could cause the 
rise the level of simvastatin in plasma. This 
could cause the increase in the risk of the 
headache.  
This adverse effect may also caused by the 
risk factor of hypertension and cardiovascular 
disease that was experienced by the patient. It 
was shown from the blood pressure data 
(160/100). Diltiazem was a calcium channel 
blocker that often used in hypertension 
medical treatment and angina pectoris. The 
mechanism of interaction was the same with 
nifedipine. Amiodarone was used for the 
patient with arrhythmia. The interaction 
mechanism of amiodarone and simvastatin 
was the same with nifedipine. Many patients 
with hypercholesterolemia also have high 
blood pressure and may be receiving 
antihypertensive therapy with calcium 
channel antagonists. Of particular note is the 
interaction of statins with mibefradil, which 
was withdrawn from the global market 
because of a range of serious drug–drug 
interactions. Several cases of statin-associated 
rhabdomyolysis were reported in patients 
receiving mibefradil 8. 
We suggest to consider the result of this study 
in the clinical practice in Indonesia. The 
healthcare professional must increase the 
monitoring of statin used in community and 
hospital by informing the adverse effects of 
statins to the patients. If patients do not get 
information about statins’ adverse effect, they 
will not realize whether the symptoms are 
related with the statins used or not. However 
result of this study is still need to be 
confirmed with larger sample sizes, longer 
period of study and based on vigilant 
surveillance. 
CONCLUSION 
Simvastatin, rosuvastatin and atorvastatin 
were well tolerated use in Yogyakarta, 
Indonesia. Only 22.9% from 157 patients 
experienced the adverse effects of statin. 
However, 8.92% patients experienced the 
adverse effects of statins’ interaction with 
other drugs, especially with antihypertension. 
The result of this study need to be confirmed 
with additional study with larger sample sizes 
and vigilant surveillance to abolish the 
toxicity of the statin. 
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